
    
      The study consisted of 2 sequential phases. Phase I was the Screening/Eligibility Phase, with
      a Screening Visit followed by an Eligibility Visit. Phase II was the treatment phase and
      included Week 1, Week 2, Week 4, and Week 8 visits. Eligible subjects were randomized in a
      1:1 ratio to receive Brinzolamide 1%/Timolol 0.5% or Brinzolamide 1% plus Timolol 0.5% two
      times a day for 8 weeks.
    
  